Lupin In Numbers

Aerial view of Lupin, Baltimore, US

#1

In Anti-TB segment globally

#1

In Cardiovascular segment in South Africa

2nd

Largest Ophthalmic player in Mexico by prescription.

3rd

Largest Indian pharmaceutical Company by revenue

4th

Largest generic pharmaceutical Company in South Africa

4th

Largest Ophthalmic player in Mexico by value.

5th

Largest generic pharmaceutical Company in US by prescription.

5th

Largest ANDA pipeline pending approval with US FDA

7th

Largest generic pharmaceutical Company by market capitalization

8th

Largest in IPM

9th

Largest generic pharmaceutical Company by sales globally

9th

Largest generic pharmaceutical Company in Japan

3.3%

Market share in IPM

11.7%

Of net sales invested in research.

17%

CAGR in Japan over last 5 years

17%

CAGR in India over last 5 years

24%

CAGR in South Africa over last 5 years

23%

CAGR in revenue over the last 10 years

29%

CAGR in profits over the last 10 years

32%

CAGR in market capitalization over the last 10 years

18

Manufacturing sites globally

343

Cumulative ANDA filing.

2525

Patents filed

6600+

specialty force in India

7000+

Lupinyts in manufacturing and quality

LEADERSHIP IN A CHANGING WORLD
Chairman's Letter

Dr. Desh Bandhu Gupta

Dr. Desh Bandhu Gupta
Founder & Chairman
Lupin Limited

"Lupin - Where leadership is a given and numbers are just milestones on a glorious path."

Leadership In A
Changing World



Dear Shareholders,

When I founded Lupin over 48 years ago, the goal was simple; to manufacture and deliver quality, affordable medicines of the highest national and social priority. It has been the core principle and guiding philosophy behind everything we have undertaken and achieved over now close to five decades... Read more

CORPORATE INFORMATION

Luin office
  • Dr. Desh Bandhu Gupta, Chairman
  • Dr. Kamal K. Sharma, Vice Chairman
  • Ms. Vinita Gupta, Chief Executive Officer
  • Mr. Nilesh Gupta, Managing Director
  • Mrs. Manju D. Gupta, Executive Director
  • Mr. Ramesh Swaminathan, Chief Financial Officer & Executive Director
  • Dr. Vijay Kelkar, Independent Director
  • Mr. R. A. Shah, Independent Director
  • Mr. Richard Zahn, Independent Director
  • Dr. K. U. Mada, Independent Director
  • Mr. Dileep C. Choksi, Independent Director
  • Mr. Jean-Luc Belingard, Independent Director
  • Mr. R. V. Satam
  • Deloitte Haskins & Sells LLP
  • Chartered Accountants
  • Dr. K. U. Mada, Chairman
  • Dr. Kamal K. Sharma
  • Mr. Dileep C. Choksi
  • Dr. Vijay Kelkar, Chairman
  • Dr. K. U. Mada
  • Dr. K. U. Mada, Chairman
  • Mr. R. A. Shah
  • Mr. Richard Zahn
  • Dr. Desh Bandhu Gupta, Chairman
  • Dr. Kamal K. Sharma
  • Mr. Nilesh Gupta
  • Dr. Vijay Kelkar
  • Dr. Kamal K. Sharma, Chairman
  • Ms. Vinita Gupta
  • Mr. Nilesh Gupta
  • Mr. Ramesh Swaminathan
  • Mr. Sunil Makharia
  • Dr. Desh Bandhu Gupta, Chairman
  • Dr. Kamal K. Sharma, Vice Chairman
  • Ms. Vinita Gupta, Chief Executive Officer
  • Mr. Nilesh Gupta, Managing Director
  • Mr. Ramesh Swaminathan, Chief Financial Officer & Executive Director
  • Mr. Shakti Chakraborty, Group President - India Region Formulations
  • Dr. Rajender Kamboj, President - Novel Drug Discovery & Development
  • Mr. Naresh Gupta, President - API & Global TB
  • Mr. Divakar Kaza, President - Human Resources
  • Mr. Alok Ghosh, President - Technical Operations
  • Dr. Cyrus Karkaria, President - Biotechnology
  • Mr. Sunil Makharia, President - Finance
  • Mr. Debabrata Chakravorty, President - Global Sourcing & Contract Manufacturing
  • Mr. Rajeev Sibal, President - India Region Formulations
  • Mr. Yugesh Goutam, President - Global Human Resources
  • Mr. Paul McGarty, President - Lupin Pharmaceuticals Inc., USA
  • Dr. Sofia Mumtaz, Head - Pipeline Management & Legal
  • Mr. Martin Mercer, President - Latin America
  • Dr. Thierry Volle, President - Europe, Middle East & Africa
  • Dr. Fabrice Egros, President - Asia Pacific & Japan
  • Dr. Kurt Nielsen, President - Somerset, USA
  • Mr. Noriaki Tsunoda, President - Kyowa Pharmaceutical Co. Ltd., Japan
  • Mr. Jean-Luc Belingard
  • Mr. Franceso Granata
  • Ms. Yvonne Greenstreet
  • Mr. Dipak Jain
  • Ernst & Young LLP
  • KPMG

REGISTERED OFFICE
Kalpataru Inspire, 3rd Floor
Off Western Express Highway
Santacruz (East), Mumbai - 400 055
Tel.: +91 22 6640 2323
Fax: +91 22 6640 8131

CORPORATE OFFICE
Laxmi Towers, ‘B’ Wing, 5th floor
Bandra Kurla Complex, Bandra (East)
Mumbai - 400 051
Tel.: +91 22 6640 2222
Fax: +91 22 6640 2130

Website
www.Lupin.com

E-Mail
info@Lupin.com

CORPORATE IDENTITY NUMBER
L24100MH1983PLC029442

Mr. Shamsher Gorawara,
Head - Corporate Communications
Email: shamshergorawara@Lupin.com

Mr. Pradeep Bhagwat
General Manager, Investors’ Services
Email: pradeepbhagwat@Lupin.com

 

TAKING CENTERSTAGE
Awards

award icon
Lupin named in the Forbes Global 2000- World’s Most Powerful Public Companies
award icon
Lupin in AON Best Employers India 2016 - amongst the Top 25 Employers
award icon
Lupin named amongst the Top 3 Research Organizations in the country Thomson Reuters India Innovation Awards 2015
award icon
Vinita Gupta, CEO & Nilesh Gupta, MD awarded the Ernst & Young Entrepreneur of the Year, India, 2015
award icon
CNBC TV18 Firm of the Year in Pharma Sector - India Risk Management Awards – 2015
award icon
Vinita Gupta awarded Outstanding Woman Business Leader of the Year - CNBC India Business Leader Awards (IBLA) FY 2015-16
award icon
Lupin named in Forbes Asia Fab 50 companies 2015 for the second year running
award icon
Vinita Gupta named in Forbes Asia Business Women Power 50 list
award icon
Lupin Limited ranked 5th in - Best at Investor Relations by FinanceAsia
award icon
Vinita Gupta named amongst The Most Powerful Business Women 2015 by Business Today
award icon
Lupin ranked 15th in the Great Places to Work Institute’s Best Companies to Work for in Asia
award icon
Ramesh Swaminathan, CFO, Lupin Limited wins the Best CFO by FinanceAsia

THE TRANSFORMATION DYNAMIC
Vice Chairman's Letter

Dr. Kamal K Sharma

Dr. Kamal K Sharma
Vice Chairman
Lupin Limited

"Confidence in people; in leadership and in innovation; we are the transformation"

The Transformation Dynamic


Vice Chairman’s Letter

Dear Shareholders,

As I write to you, what is certain and a given is that we are living in an increasingly uncertain and volatile world leading to huge amount of complexity and ambiguity with enhanced amplitude and frequency. This poses a special challenge to the process of designing growth strategies and planning of operations. Institutions around the globe are continuously being pushed to change; if they do not proactively do so... Read more

POWERING UP
Chief Executive Officer & MD's Letter

Vinita and Nilesh Gupta

Vinita Gupta, Nilesh Gupta

Chief Executive Officer, Managing Director
Lupin Limited

"16,000+ Lupinytts believe that their best is yet to come. We are powering up to embrace our future as a specialty pharmaceutical major"

Powering Up


Chief Executive Officer and Managing Director’s Letter

Dear Shareholders,

FY 2016 was a very important year for Lupin and marked the beginning of a new era in Lupin’s evolution as a global pharmaceutical powerhouse. A transformational year, which saw us accelerate our efforts to increase depth and expand our presence in key markets such as US, India and Japan thus adding to our leadership credentials... Read more

THE PERFORMANCE MATRIX
Financial Highlights 2016


The Performance Matrix


Financial Highlights 2016
FY16
137,016
FY15
125,997
FY14
110,866
FY13
94,616
FY12
69,597

 

Net sales ( Millions) CAGR 18.5%

API
Domestic Formulations
Emerging Markets Formulations
Advance Markets Formulations

Revenue Compositions (%)

FY16
25
47
28
FY15
25
49
26
FY14
27
48
25
FY13
29
44
27
FY12
29
41
30
Exports - Emerging Markets
Exports - Advanced Markets
Domestic

Geographic Break Down
(% Contribution) (FML + API)

FY16
39,412
FY15
38,593
FY14
31,193
FY13
22,977
FY12
14,591

 

EBITDA ( million) CAGR 28.2%

FY16
34,330
FY15
34,148
FY14
28,317
FY13
19,246
FY12
11,960

 

Profit Before Tax ( million) CAGR 30.2%

FY16
22,707
FY15
24,032
FY14
18,364
FY13
13,142
FY12
8,676

 

Net Profit ( million) CAGR 27.2%

FY16
17,318
48,544
FY15
11,186
37,358
FY14
9,583
27,785
FY13
7,708
20,067
FY12
5,940
14,127
Current year
Past year

 

Cumulative R&D ( million)

FY16
11,681
37,438
FY15
7,582
29,856
FY14
4,376
25,480
FY13
4,871
20,609
FY12
5,514
15,095
Current year
Past year

 

Cumulative Capex ( million)

FY16
375
FY15
375
FY14
300
FY13
200
FY12
160

 

Dividend (%)

FY16
50.45
FY15
53.54
FY14
40.99
FY13
29.39
FY12
19.43

 

Earning Per Share () CAGR 26.9%

ADDING MUSCLE
United States

Adding Muscle - United states
"Novel Laboratories facility, Somerset, New Jersey, USA"

Adding Muscle


United States

Lupin by numbers in united states

The US is Lupin’s largest and most important market and integral to the Company’s performance. Headquartered in Baltimore, Maryland, the Company’s us subsidiary, Lupin pharmaceuticals, inc. (lpi), is dedicated to delivering high-quality, branded and generic medicines trusted by healthcare professionals and patients across the US. Read more

PASSION TO PERFORM
India

Passion to perform
"Lupin India's medical representatives at a pharmacy"

Passion to perform


India

Passion to perform

India is Lupin’s 2nd largest business by revenues and contributed 25% of the Company’s global revenues during FY 2016... Read more

The Next Growth Multiplier
Asia Pacific (APAC)

Lupin Asia Pacific
"Lupin's Sanda facility, Japan"

The Next Growth Multiplier


Asia Pacific (APAC)

Lupin Asia Pacific by numbers

Lupin’s Asia pacific (APAC) region includes important businesses such as the Company’s 3rd largest market japan followed by the Philippines and Australia. APAC contributed 13% of Lupin's global revenues, recording sales of 17,767 million during FY 2016, a CAGR of 15% over the last 4 years... Read more

GARNERING PACE
Europe, Middle East & Africa (EMEA)

Lupin Lupin Europe Middle East And Africa

Garnering Pace


Europe, Middle-East & Africa (EMEA)

Lupin Lupin Europe Middle East And Africa by numbers

Headquartered in Zug, Switzerland, Lupin’s EMEA business covers the markets of Europe, Middle-East Asia & Africa. Lupin EMEA recorded revenues of 8,863 million During FY 2016, contributing 6% of the Company’s global revenues. Read more

EXPANDING HORIZONS
Latin America (LATAM)

Latin America-latam - Lupin
"Scientists at the Medquímica facility, Brazil"

Expanding Horizons


Latin America (LATAM)

Lupin Lupin Europe Middle East And Africa by numbers

Latin America (latam) represents Lupin’s youngest business globally with the Company having established operations in the region`s two largest markets, Mexico and Brazil through its subsidiaries medquímica indústria farmacêutica s.a., Brazil, (Medquímica) and laboratories grin S.A. de C.V. (grin) in Mexico. Read more

A STRONG FOUNDATION
Global API Business

Lupinytt at work at our Indore facility, India
"Lupinyts at work at our Indore facility, India"

A Strong Foundation


Global Active Pharmaceutical Ingredients Business

Global Active Pharmaceutical Ingredients Business

India has emerged as the best quality manufacturer of active pharmaceutical Ingredients (api) as compared to its European and Chinese counterparts. Recent studies indicate that the Indian api industry is set for significant growth with the country emerging as the leading and most favored supplier of formulations to advanced markets such as the US and Europe. Read more

ALCHEMY FOR GROWTH
Research & Development

Research and Development - Lupin

Alchemy For Growth


Research and Development

Research and Development by numbers

We are living in an era of unparalleled scientific progress and technology advances. The global pharmaceutical industry is on the cusp of an era of significant transformation. No longer is it being shaped by just aging populations, spiraling healthcare costs, increase in chronic diseases or change in disease patterns, but also by discoveries, inventions in technology, communications, systems and software. Read more

ENGINEERED FOR EXCELLENCE
Global Manufacturing & Supply Chain

Lupinytt at Biotech manufacturing facility, Pune, India
Lupinytt at Biotech manufacturing facility, Pune, India

Engineered For Excellence


Global Manufacturing & Supply Chain

Engineered For Excellence by numbers - Lupin

Lupin has been built on the on the bedrock of over 4 decades of a quality driven, market and customer centric manufacturing ethic. We have grown and expanded our business by continuously developing and firming up the foundations of our global manufacturing network by imbibing and assimilating best practices as laid down by regulators, infusing systems, technology and... Read more

PEOPLE FIRST
Human Resources

Lupin's global diversified workforce
Lupin's global diversified workforce

People First


Human Resources

People First by numbers - Lupin

Our commitment to building a world-class organization and delivering a unique value proposition for our employees has translated into a culture of high performance and continuous learning, where every employee feels valued and invested in... Read more

Social Conscience
Corporate Social Obligation

Rural woman working at a poultry farm supported by LHWRF
Rural woman working at a poultry farm supported by LHWRF

Social Conscience


Corporate Social Obligation

Corporate Social Responsibility by numbers - Lupin

Much of what happens in our world is the result of how we think, feel and act – about others and about ourselves. When you put your faith in people, give what You have learnt and give freely, then good things begin to happen... Read more

A BALANCED RECIPE
CFO & Executie Director's Letter - Financial Review

Ramesh Swaminathan - Chief Financial Officer & Executive Director, Lupin

Ramesh Swaminathan
Chief Financial Officer & Executive Director
Lupin Limited

"Lupin’s sustained growth performace and focus on operational excellence has resulted in outstanding shareholders return of over 15 times in the last 10 years"

A Balanced Recipe


Chief Financial Officer & Executive Director’s Letter – Financial Review

Business performance & balance sheet highlights

Our business operations continue to unlock and deliver value enabling us to drive growth across key markets globally. FY 2016 saw Lupin maintain its upward growth trajectory in spite of a very challenging and weak global economic environment... Read more

Reports And Financials
Business Overview


Reports And Financials


BUSINESS OVERVIEW

Contact info


Contact info


 

Mr. Shamsher Gorawara
Head - Corporate Communications
Email: shamshergorawara@lupin.com

Mr. Pradeep Bhagwat
General Manager, Investors’ Services
Email: pradeepbhagwat@lupin.com

Show/hide the menu